| Literature DB >> 28640884 |
Dulcinea Maria Barbosa Campos1, Alverne Passos Barbosa2, Jayrson Araújo de Oliveira3, Giovana Galvão Tavares1, Pedro Vitor Lemos Cravo1,2,4, Alejandro Luquetti Ostermayer2.
Abstract
Lagochilascariasis is a parasitic disease caused by a helminth of the order Ascaroidea, genus Lagochilascaris that comprises 6 species, among which only Lagochilascaris minor Leiper, 1909, is implicated in the human form of the disease. It is remarkable that the majority of cases of human lagochilascariasis in the Americas have been reported in Brazil. The natural definitive hosts of this parasite seem to be wild felines and canines. Lagochilascariasis is mostly a chronic human disease that can persist for several years, in which the parasite burrows into the subcutaneous tissues of the neck, paranasal sinuses, and mastoid. L. minor exhibits remarkable ability to migrate through the tissues of its hosts, destroying even bone tissue. Fatal cases have been described in which the parasite was found in the lungs or central nervous system. Treatment is often palliative, with recurrence of lesions. This paper summarizes the main features of the disease and its etiologic agent, including prevalence, life cycle, clinical course, and treatment.Entities:
Mesh:
Year: 2017 PMID: 28640884 PMCID: PMC5480834 DOI: 10.1371/journal.pntd.0005510
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Fig 1Geographical distribution of human lagochilascariasis in the Americas.
Fig 2Cervical lesion draining pus in a patient infected with Lagochilascaris minor.
Fig 3Adult worm of Lagochilascaris minor migrating from the mastoid to the external auditory meatus.
Fig 4Lagochilascaris minor infecting egg in the intestinal lumen of an experimentally infected mouse.
Fig 5Third stage larvae of the Lagochilascaris minor crossing the cecal mucosa of an experimentally infected mouse.
Fig 6Third stage larva in the hepatic parenchyma of an experimentally infected mouse.
Fig 7Mouse infected with Lagochilascaris minor eggs.
Granulomatous nodules containing third stage larvae in the muscles and cellular subcutaneous tissue.
Fig 8Life cycle of Lagochilascaris minor.
Parasite eggs are eliminated from the host organism through feces (1), undergo division (2), and develop into the infecting stage (3). The infecting egg may be either orally inoculated into the mouse (4) or contaminate the environment (6). In experimental infection, granulomatous nodules containing third stage larvae are observed in the muscles and subcutaneous tissue of a mouse infected with the helminth (4A). Experimental definitive hosts are infected through ingestion of intermediate hosts containing third stage-encysted larvae (5). Once in the environment (6), infecting eggs are ingested by wild rodents (7). Wild felines/canines ingest intermediate hosts containing third stage larvae and eliminate parasite eggs in the environment through feces (8). Human infection originates from the ingestion of uncooked or partially cooked meat of wild rodents containing encysted larvae (9).
Drugs used against lagochilascariasis.
Therapeutic protocols in 20 patients infected by Lagochilascaris minor.
| ABSCESS | DRUGS | DOSES | EVOLUTION | REF | |
|---|---|---|---|---|---|
| 1 | CR and NS | diethylcarbamazine | Three 50 mg tablets three times a day (1,000 tablets) | Chronic disease | [ |
| 2 | CR | thiabendazole | 500 mg twice a day for 3 successive days | Patient died | [ |
| 3 | CR | 50 mg/Kg of body weight a day for 5 days | No follow-up | [ | |
| 4 | Ms, ME and CNS | 50 mg/Kg of body weight a day for 2 days | Patient died | [ | |
| 5 | Ms, ME, CR and CNS | 2,000 mg/24 h | Patient died | [ | |
| 6 | CR | levamisole | 150 mg a day for 3 days | Probable cure | [ |
| 7 | SMR | pyrantel pamoate | 700 mg for 5 days | No follow-up | [ |
| 8 | CR | levamisole | 150 mg a day for 4 weeks | Probable cure | [ |
| 9 | NS | albendazole | 400 mg (single dose) | No cure | [ |
| 10 | Ms | 400 mg once a day for 30 days | No follow-up | [ | |
| 11 | CR | thiabendazole | 500 mg twice a day for 3 days | No cure | [ |
| diethylcarbamazine | 100 mg three times a day for 144 days | Probable cure | |||
| 12 | Ms | thiabendazole | 500 mg three times a day for 6 days | No cure | [ |
| diethylcarbamazine | 100 mg two times a day | Probable cure | |||
| 13 | NS and Ms | thiabendazole | 50 mg/Kg of body weight a day for 5 weeks | No cure | [ |
| levamisole | 50 mg daily for 10 days | No cure | |||
| 150 mg a week for 3 months | Probable cure | ||||
| 14 | CR | levamisole | 2.5 mg/Kg of body weight a day for 15 days | No follow-up | [ |
| and | |||||
| praziquantel | 15 mg/Kg of body weight (single dose) | ||||
| 15 | CR | thiabendazole | 25 mg/Kg of body weight once a day for 10 days | No cure | [ |
| levamisole | 150 mg once a day for 10 days | No cure | |||
| albendazole | 400 mg once a day for 36 days | Probable cure | |||
| 16 | NS | thiabendazole | 30 mg/Kg of body weight a day for 3 days (poorly tolerated) | [ | |
| No cure | |||||
| 15 mg/Kg a day for 6 days | |||||
| mebendazole | 200 mg/day for 4 days | No cure | |||
| levamisole | 150 mg 3 times daily for 8 days | Probable cure | |||
| 150 mg twice daily on 3 days of each week for the following 12 weeks | |||||
| 17 | ME, CNS | Associations: | [ | ||
| mebendazole thiabendazole | 100 mg twice a day for 3 days | No cure | |||
| 50 mg/Kg of body weight a day for 2 days | |||||
| levamisole cambendazole | 2.5 mg/Kg of body weight a day for 30 days | ? | |||
| 18 | Ms, TB and CNS | cambendazole | Four cycles of 30 mg/Kg of body weight a day for five days, repeated after a 10-day interval | No cure | [ |
| levamisole | 150 mg por daily for 10 days, then 150 mg once a week for 3 months | No cure | |||
| ivermectin | Two cycles of four doses of 0.2 mg/Kg of body weight at weekly intervals, followed by a month without therapy; monthly doses thereafter for 6 months | Probable cure | |||
| 19 | CR | ivermectin | 300 μg/Kg of body weight at weekly intervals for 12 weeks | Probable cure | [ |
| 20 | NS, Ms and ME | ivermectin | 200 μg/Kg of body weight for 1 week | No follow-up | [ |
| and | |||||
| thiabendazole | 1 tab a day for 3 days, repeating after 15 days |
CR = cervical region, NS = nasal sinuses, Ms = mastoid, ME = middle ear, TS = tonsil, TB = temporal bone, SMR = Sub Maxillary Region, CNS = central nervous system.